VRTX Vertex Pharmaceuticals
- 400.160
- -1.980-0.49%
- 399.420
- -0.740-0.18%
Vertex Pharmaceuticals News
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 9.66% on an annualized basis producing an average annual return of 19.99%. Currently, Vertex Pharmaceuticals
Form 144 | Vertex Pharmaceuticals(VRTX.US) Director Proposes to Sell 188.18K in Common Stocks
SEC FILLINGS DISCLOSED/ May 2, $Vertex Pharmaceuticals(VRTX.US)$ Director Bhatia Sangeeta N. intends to sell 467 shares of its common stock on May 2, with a total market value of approximately $188.18
Analysts Offer Insights on Healthcare Companies: Accolade (ACCD), Vertex Pharmaceuticals (VRTX) and Zimmer Biomet Holdings (ZBH)
Those Who Invested in Vertex Pharmaceuticals (NASDAQ:VRTX) Five Years Ago Are up 127%
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shareholders might be concerned after seeing the share price drop 11% in the last quarter. But in stark contrast, the returns over the last half de
J&J, Roche, AstraZeneca Poised to Have Highest Orphan Drug Sales by End of Decade
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Vertex Pharmaceuticals Inc's (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, potentially extending the lives of some patients by up to 45 years. Despite
Express News | Vertex Announces European Commission Approval for Kalydeco® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest
Vertex Pharmaceuticals's (NYSE:VRTX) short percent of float has fallen 3.75% since its last report. The company recently reported that it has 3.98 million shares sold short, which is 1.54% of all regu
9 Stocks That Thrive When Interest Rates Are Higher -- Barrons.com
The prospect of elevated interest rates for longer has dented the broader stock market -- but history shows that is also the perfect environment for a select group of stocks to ga
9 Stocks That Thrive When Interest Rates Are Higher
Though economic stress could be on the way, a few groups of stocks can benefit.
Regeneron to Collaborate on Gene Editing Therapies With Doudna-founded Mammoth
VERTEX UND TREEFROG THERAPEUTICS GEBEN LIZENZVEREINBARUNG UND ZUSAMMENARBEIT ZUR OPTIMIERUNG DER PRODUKTION DER ZELLTHERAPIEN VON VERTEX FÜR TYP-1-DIABETES BEKANNT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) und TreeFrog Therapeutics gaben heute bekannt, dass Vertex eine exklusive Lizenz für TreeFrogs...
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1454 ET - Vertex Pharmaceuticals seems not to have explored al
Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk
1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a res
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Vertex In-licenses Cell Therapy Technology for Diabetes Candidates
Vertex Y Treefrog Therapeutics Anuncian Un Acuerdo Para La Producción De Las Terapias Celulares De Vertex
Vertex y Treefrog Therapeutics anuncian un acuerdo de licencia y colaboración para optimizar la producción de las terapias celulares de Vertex para la diabetes tipo 1Vertex obtiene una licencia exc
Analysis
Price Target
No Data
